Explore the benefits and considerations of adjuvant immunotherapy in the treatment of resectable non-small cell lung cancer (NSCLC). Review the latest clinical trials, including IMpower 010 and Checkmate 816, and learn about the potential role of neoadjuvant therapy.

11 views • 28 slides

Zongertinib (BI.1810631) Phase I Study in Advanced Solid Tumors with HER2 Aberrations focusing on NSCLC. The trial involves dose escalation and expansion, testing different doses in cohorts with varied HER2 mutations. Primary endpoints include MTD, OR, and DLTs.

2 views • 14 slides

HER2 activation plays a crucial role in promoting tumor proliferation and survival in NSCLC. Driven by oncogenic downstream signaling pathways, HER2 overexpression and gene amplification lead to the formation of heterodimers and activation of key signaling cascades. Additionally, HER2 mutations are

0 views • 36 slides

Selpercatinib 40 & 80 mg is an innovative targeted therapy designed to inhibit RET gene mutations, providing a highly precise treatment option for patients with non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and RET fusion-positive thyroid cancers. Now available as Selpercatinib

0 views • 11 slides

Examining the role of adjuvant therapies in stage IB-IIIA non-small cell lung cancer (NSCLC) post-surgery. Discussion includes the impact of chemotherapy and radiation therapy on overall survival rates and the historical context of adjuvant treatment decisions. Management strategies and consideratio

0 views • 30 slides